APA

Arif S. H., Pandith A. A., Tabasum R., Ramzan A. U., Singh S., Siddiqi M. A. & Bhat A. R. (022018). WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. : Journal of neurosurgical sciences.

Chicago

Arif Sajad H, Pandith Arshad A, Tabasum Rehana, Ramzan Altaf U, Singh Sarabjeet, Siddiqi Mushtaq A and Bhat Abdul R. 022018. WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. : Journal of neurosurgical sciences.

Harvard

Arif S. H., Pandith A. A., Tabasum R., Ramzan A. U., Singh S., Siddiqi M. A. and Bhat A. R. (022018). WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. : Journal of neurosurgical sciences.

MLA

Arif Sajad H, Pandith Arshad A, Tabasum Rehana, Ramzan Altaf U, Singh Sarabjeet, Siddiqi Mushtaq A and Bhat Abdul R. WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. : Journal of neurosurgical sciences. 022018.